Getting a medical device to market in the United States requires FDA authorization, but the specific pathway depends on how much risk your device poses to patients. The FDA classifies roughly 1,700 types of devices into three risk-based categories, and each category has a different regulatory route with different costs, timelines, and evidence requirements. Understanding which path applies to your device is the single most important step in the process.
How the FDA Classifies Medical Devices
The FDA assigns every device to one of three classes based on the risk it poses to patients and users. Class I covers the lowest-risk devices, things like tongue depressors and elastic bandages. These require only general controls such as proper labeling and manufacturing standards. Most Class I devices are exempt from premarket review entirely.
Class II devices carry moderate risk and need both general controls and special controls, which can include performance standards, post-market surveillance, or specific labeling requirements. Surgical drapes, powered wheelchairs, and clinical thermometers fall into this category. Class II is the largest group and typically requires a 510(k) premarket notification.
Class III is reserved for the highest-risk devices: those that sustain or support life, are implanted, or present a potentially unreasonable risk. Pacemakers and replacement heart valves are classic examples. These devices require the most rigorous pathway, called premarket approval (PMA), which demands clinical trial data proving safety and effectiveness.
The Three Main Pathways to Market
510(k) Premarket Notification
The 510(k) is the most common route and applies to most Class II devices. The core requirement is demonstrating that your device is “substantially equivalent” to a device already legally marketed in the U.S., known as a predicate device. Substantial equivalence means your device has the same intended use and either the same technological characteristics as the predicate, or different characteristics that don’t raise new safety or effectiveness concerns. You’ll need to submit performance testing data showing your device works at least as well as the predicate, but you typically won’t need clinical trial data unless the technological differences are significant.
The FDA’s target review time for 510(k) submissions is 112 calendar days total (including time for both FDA review and any responses you need to provide). The agency aims to issue a decision within 90 FDA business days for 95% of submissions. The standard application fee for fiscal year 2026 is $26,067, or $6,517 if you qualify as a small business.
Premarket Approval (PMA)
PMA is the strictest pathway and applies to Class III devices. Unlike a 510(k), a PMA requires you to prove your device is safe and effective on its own merits, not just equivalent to something already on the market. This means submitting both nonclinical laboratory data (biocompatibility testing, stress testing, shelf life studies, sterilization validation) and clinical investigation data from human trials. Your clinical data must include subject selection criteria, demographics, safety and effectiveness outcomes, adverse reactions, device failures, and statistical analyses.
The PMA timeline is substantially longer. The FDA’s target total time to decision is 285 calendar days for submissions received in fiscal years 2025 through 2027. For submissions that require input from an advisory committee of outside experts, the FDA allows up to 320 business days. The standard PMA fee is $579,272. Small businesses pay $144,818, and companies with gross receipts under $30 million can have the fee waived entirely on their first PMA application.
De Novo Classification
The De Novo pathway exists for novel devices that are low-to-moderate risk but have no predicate device on the market. If your device doesn’t fit neatly into an existing category and doesn’t warrant the full rigor of a PMA, De Novo lets the FDA evaluate it and classify it into Class I or Class II. You’ll need to submit a device description, bench performance testing, and a detailed argument for why general controls (or general plus special controls) are sufficient to ensure safety and effectiveness. Clinical data may be required depending on the device.
You can submit a De Novo request directly if you’ve determined there’s no suitable predicate, or after receiving a “not substantially equivalent” determination on a 510(k). The standard fee is $173,782, with a small business rate of $43,446. Once granted, your device becomes the predicate for future 510(k) submissions from other companies.
Running a Clinical Trial Under an IDE
If your device requires clinical data, whether for a PMA or occasionally for a 510(k) or De Novo, you’ll need an Investigational Device Exemption (IDE) before enrolling any patients. All clinical evaluations of investigational devices require an investigational plan approved by an institutional review board (IRB), informed consent from every participant, labeling that clearly states the device is for investigational use only, ongoing study monitoring, and detailed recordkeeping.
For significant risk devices, the IDE must also be approved by the FDA itself before the study begins. Non-significant risk devices can proceed with IRB approval alone. Planning for an IDE early is critical because clinical trials are by far the most time-consuming and expensive part of the process. Depending on the device, trials can take one to several years to complete and often represent the majority of total development cost.
Quality Management System Requirements
Regardless of which pathway you follow, you must have a quality management system (QMS) in place that meets FDA requirements. As of February 2026, the FDA’s Quality Management System Regulation incorporates the international standard ISO 13485:2016, which is the same standard used by regulators in Europe and many other countries. This means a single quality system can now serve you across multiple markets.
Your QMS must cover design and development controls, production processes, purchasing, corrective and preventive actions, and risk management throughout the device lifecycle. Design controls apply even during the investigational stage, so your QMS needs to be functional before you begin clinical trials. The FDA inspects manufacturing facilities to verify compliance, and quality system failures are one of the most common reasons companies face enforcement actions.
Facility Registration and Device Listing
Once your device is cleared or approved, every establishment involved in producing or distributing the device for the U.S. market must register with the FDA annually and list the specific devices manufactured there. This applies to domestic and foreign facilities alike. Registration and listing must be submitted electronically, and you’ll need to include your premarket submission number (510(k), De Novo, or PMA) for each listed device. The FDA charges an annual registration fee, though small businesses with gross receipts under $1 million may qualify for a waiver if they can demonstrate financial hardship.
Costs Beyond User Fees
FDA application fees are only a fraction of total cost. The real expense lies in testing, clinical trials, regulatory consulting, and building out your quality system. A straightforward 510(k) for a well-understood device type might cost $50,000 to $150,000 in total when you factor in performance testing and regulatory preparation. A PMA with a full clinical trial can easily run into the millions.
Small businesses have several financial advantages worth pursuing. Companies with gross receipts of $100 million or less qualify for reduced application fees across all submission types. Those under $30 million can have their first PMA fee waived. To access these benefits, you must certify your small business status through the FDA’s Small Business Determination program using Form 3602N, which became the required form starting August 2025.
Steps to Work Through in Order
- Classify your device. Use the FDA’s product classification database to identify the three-digit product code and regulatory class for your device type. This determines which pathway applies.
- Identify your regulatory pathway. Class I devices are often exempt. Class II devices typically need a 510(k). Class III devices need a PMA. Novel devices without a predicate may use De Novo.
- Build your quality management system. Establish ISO 13485-compliant processes for design, production, and risk management before you begin testing or trials.
- Conduct testing. Perform bench testing, biocompatibility studies, and any other nonclinical evaluations relevant to your device type. For PMA devices, apply for an IDE and run clinical trials.
- Prepare and submit your application. Use the FDA’s electronic Submission Template and Resource (eSTAR) to compile your submission with all required sections.
- Respond to FDA questions. Expect at least one round of additional information requests. Your responsiveness directly affects total review time.
- Register your facility and list your device. Complete this step before you begin commercial distribution.
Pre-submission meetings with the FDA are available and highly recommended, especially for PMA and De Novo submissions. These meetings let you discuss your testing strategy, clinical trial design, and any classification questions before you invest heavily in data generation. Getting early alignment with the FDA on what evidence they expect can save months of rework.